William I Sivitz1, Lawrence S Phillips2,3, Deborah J Wexler4, Stephen P Fortmann5, Anne W Camp6, Margaret Tiktin7, Magalys Perez6, Jacqueline Craig8, Priscilla A Hollander9, Andrea Cherrington10, Vanita R Aroda11, Meng Hee Tan12, Jonathan Krakoff13, Neda Rasouli14, Nicole M Butera15, Naji Younes15. 1. University of Iowa, Iowa City, IA grademail@bsc.gwu.edu. 2. Atlanta VA Medical Center, Decatur, GA. 3. Emory University School of Medicine, Atlanta, GA. 4. Diabetes Clinical Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 5. Kaiser Permanente Northwest, Portland, OR. 6. Fair Haven Community Health Care, New Haven, CT. 7. Case Western Reserve University, Cleveland, OH. 8. University of Cincinnati, Cincinnati, OH. 9. Baylor Research Institute, Dallas, TX. 10. University of Alabama, Birmingham, AL. 11. MedStar Health Research Institute, Hyattsville, MD. 12. University of Michigan, Ann Arbor, MI. 13. Southwestern American Indian Center, Phoenix, AZ. 14. University of Colorado, Denver, CO. 15. Department of Biostatistics and Bioinformatics, The Biostatistics Center, Milken Institute School of Public Health, The George Washington University, Rockville, MD.
Abstract
OBJECTIVE: We evaluated the effect of optimizing metformin dosing on glycemia and body weight in type 2 diabetes. RESEARCH DESIGN AND METHODS: This was a prespecified analysis of 6,823 participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) taking metformin as the sole glucose-lowering drug who completed a 4- to 14-week (mean ± SD 7.9 ± 2.4) run-in in which metformin was adjusted to 2,000 mg/day or a maximally tolerated lower dose. Participants had type 2 diabetes for <10 years and an HbA1c ≥6.8% (51 mmol/mol) while taking ≥500 mg of metformin/day. Participants also received diet and exercise counseling. The primary outcome was the change in HbA1c during run-in. RESULTS: Adjusted for duration of run-in, the mean ± SD change in HbA1c was -0.65 ± 0.02% (-7.1 ± 0.2 mmol/mol) when the dose was increased by ≥1,000 mg/day, -0.48 ± 0.02% (-5.2 ± 0.2 mmol/mol) when the dose was unchanged, and -0.23 ± 0.07% (-2.5 ± 0.8 mmol/mol) when the dose was decreased (n = 2,169, 3,548, and 192, respectively). Higher HbA1c at entry predicted greater reduction in HbA1c (P < 0.001) in univariate and multivariate analyses. Weight loss adjusted for duration of run-in averaged 0.91 ± 0.05 kg in participants who increased metformin by ≥1,000 mg/day (n = 1,894). CONCLUSIONS: Optimizing metformin to 2,000 mg/day or a maximally tolerated lower dose combined with emphasis on medication adherence and lifestyle can improve glycemia in type 2 diabetes and HbA1c values ≥6.8% (51 mmol/mol). These findings may help guide efforts to optimize metformin therapy among persons with type 2 diabetes and suboptimal glycemic control.
OBJECTIVE: We evaluated the effect of optimizing metformin dosing on glycemia and body weight in type 2 diabetes. RESEARCH DESIGN AND METHODS: This was a prespecified analysis of 6,823 participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) taking metformin as the sole glucose-lowering drug who completed a 4- to 14-week (mean ± SD 7.9 ± 2.4) run-in in which metformin was adjusted to 2,000 mg/day or a maximally tolerated lower dose. Participants had type 2 diabetes for <10 years and an HbA1c ≥6.8% (51 mmol/mol) while taking ≥500 mg of metformin/day. Participants also received diet and exercise counseling. The primary outcome was the change in HbA1c during run-in. RESULTS: Adjusted for duration of run-in, the mean ± SD change in HbA1c was -0.65 ± 0.02% (-7.1 ± 0.2 mmol/mol) when the dose was increased by ≥1,000 mg/day, -0.48 ± 0.02% (-5.2 ± 0.2 mmol/mol) when the dose was unchanged, and -0.23 ± 0.07% (-2.5 ± 0.8 mmol/mol) when the dose was decreased (n = 2,169, 3,548, and 192, respectively). Higher HbA1c at entry predicted greater reduction in HbA1c (P < 0.001) in univariate and multivariate analyses. Weight loss adjusted for duration of run-in averaged 0.91 ± 0.05 kg in participants who increased metformin by ≥1,000 mg/day (n = 1,894). CONCLUSIONS: Optimizing metformin to 2,000 mg/day or a maximally tolerated lower dose combined with emphasis on medication adherence and lifestyle can improve glycemia in type 2 diabetes and HbA1c values ≥6.8% (51 mmol/mol). These findings may help guide efforts to optimize metformin therapy among persons with type 2 diabetes and suboptimal glycemic control.
Authors: Vanita R Aroda; Sharon L Edelstein; Ronald B Goldberg; William C Knowler; Santica M Marcovina; Trevor J Orchard; George A Bray; David S Schade; Marinella G Temprosa; Neil H White; Jill P Crandall Journal: J Clin Endocrinol Metab Date: 2016-02-22 Impact factor: 5.958
Authors: Andrew McGovern; Zayd Tippu; William Hinton; Neil Munro; Martin Whyte; Simon de Lusignan Journal: Diabetes Obes Metab Date: 2017-12-12 Impact factor: 6.577
Authors: D Williams-Herman; J Johnson; R Teng; G Golm; K D Kaufman; B J Goldstein; J M Amatruda Journal: Diabetes Obes Metab Date: 2010-05 Impact factor: 6.577
Authors: Juan P Frias; Zachary Zimmer; Raymond L H Lam; Guillermo Amorin; Catherine Ntabadde; Carol Iredale; Edward A O'Neill; Samuel S Engel; Keith D Kaufman; Hideo Makimura; Michael F Crutchlow Journal: Diabetes Obes Metab Date: 2019-02-17 Impact factor: 6.577